Berberine, an isoquinoline alkaloid, has been reported to ameliorate various autoimmune diseases including rheumatoid arthritis by oral administration. However, its mechanism remains mysterious due to an extremely low bioavailability. The fact that berberine readily accumulates in the gut, the largest endocrine organ in the body, attracted us to explore its antiarthritic mechanism in view of the induction of intestinal immunosuppressive neuropeptides. In this study, berberine (200 mgÁkg À1 , i.g.) was shown to ameliorate collagen-induced arthritis in rats, which was manifested by the reduction of clinical signs and joint destruction, as well as marked down-regulation of Th17 cell frequency and interleukin-17 level in blood. In contrast, an intravenous injection of berberine failed to affect arthritis in rats, implying that its anti-arthritic effect was gut-dependent. Further studies revealed that oral berberine selectively elevated the levels of cortistatin, of five gut-derived neuropeptides tested, in the intestines and sera of arthrititic rats. Antagonists of ghrelin/growth hormone secretagogue receptor 1 (a subtype of cortistatin receptor) almost completely abolished the ameliorative effect of berberine on arthritis and Th17 cell responses in rats.
Introduction
Rheumatoid arthritis (RA) is a chronic progressive disease characterized by synovial inflammation, autoantibody production, and cartilage and bone destruction.
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in patients with RA [1] . Although RA is the most common autoimmune inflammatory arthritis in adults, the etiology remains unclear [2] . Established and emerging data have shown that RA involves a complex interplay among genotype, environmental triggers, the immune system, and even neuroendocrine factors [3] [4] [5] . Conventionally, adaptive immunity, especially a Th1 cell response, is considered to lie at the center of early pathogenesis, but in addition, attention is increasing focusing on the role of Th17 cells. An imbalance between Th17 and regulatory T cells (Treg cells) has been extensively recognized in both patients and animal models of RA.
Berberine is an isoquinoline alkaloid that is found in many medicinal plants, such as Coptis chinensis, Phellodendron japonicum, and Berberis aquifolium. These plants have been used as folk medicines for the treatment of gastrointestinal disorders including diarrhea and gastroenteritis for centuries in Asian countries [6] . Recently, berberine was reported to ameliorate the clinical signs of rats with collagen-induced arthritis (CIA) by an oral administration at 200 mgÁkg À1 [7] . Several in vitro studies suggested that the anti-arthritic effect of berberine was mediated by apoptotic induction of dendritic cells and proliferation inhibition of fibroblast-like synoviocytes [8, 9] . However, a poor absorption of berberine resulted in an extremely low bioavailability (under 1%). When it was orally administered in rats at a dose of 200 mgÁkg À1 , the peak plasma concentration was less than 0.06 lM [10, 11] , which was far from its minimal effective concentration in vitro (1-50 lM). This has meant that the anti-arthritic mechanism of berberine is in need of further illustration. Accumulating evidence suggests that intestinal neuropeptides participate in the regulation of appetite, inflammation, and energy homeostasis [12] . Neuropeptides are widely produced by central and peripheral neurons alongside endocrine cells in the gastrointestinal tract and act as neurotransmitters or gut hormones. In autoimmune disorders, neuropeptides such as vasoactive intestinal polypeptide (VIP), ghrelin, and cortistatin (CST) have been proven to play important roles in regulating the balance of proinflammatory and antiinflammatory responses as well as the balance of Th17 and Treg cells [13, 14] . For example, an intraperitoneal injection of VIP enhanced the CD4 + CD25 + Treg response and reduced the Th17-and Th1-type responses during rat CIA [15, 16] . Ghrelin could suppress Th17 cell differentiation and down-regulate the expression of proinflammatory cytokines [17, 18] . CST stimulated interleukin (IL)-10 production in trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis and impaired Th1 and Th17 responses in experimental autoimmune encephalomyelitis (EAE) of mice [19, 20] . These findings suggest that targeting the generation of neuropeptides from gut might be a promising therapeutic strategy for autoimmune disorders like RA.
Considering the pharmacokinetic characteristics of oral berberine (very poor plasma exposure and high content of prototype in feces) [21] and the suppressive effects of gastrointestinal neuropeptides on systemic autoimmune responses, we proposed a hypothesis that orally administered berberine might accumulate in the intestinal tract and promote the generation of antiinflammatory and immunosuppressive neuropeptides and hence exert an anti-arthritic effect. This study was performed to verify this hypothesis, to unravel the unique mode of action of berberine's anti-arthritic effect, and to provide a reasonable explanation for the therapeutic potential against systemic autoimmune diseases of compounds with a similar pharmacokinetic profile to berberine.
Results

Berberine attenuated the clinical symptoms of CIA rats
We first examined the anti-arthritic effect of orally administered berberine in CIA rats. Daily treatment with berberine (200 mgÁkg À1 ), starting from the onset of clinical signs, attenuated disease progression and reduced the disease severity by roughly 50% (Fig. 1A) . According to hematoxylin and eosin (HE) staining analysis and radiological scanning, berberine-treated rats showed decreased histological scores and joint destruction scores in comparison with vehicle-treated model rats (Fig. 1B-D) . Quantitative PCR analysis showed that mRNA expressions of receptor activator of nuclear factor jB ligand (RANKL), tumor necrosis factor a (TNF-a), IL-6 and IL-1b were higher in synovium of CIA rats, and berberine treatment significantly down-regulated the expressions (Fig. 1E,F) . Berberine also decreased the levels of serum proinflammatory cytokines, such as TNF-a, IL-6, and IL-1b (Fig. 1G ). Leflunomide showed a similar ameliorative effect on disease severity, histological changes, and joint destruction. To summarize, oral berberine exerted substantial anti-arthritic effects on rat CIA with a potency near to a lower dose of leflunomide.
Berberine inhibited Th17 cell response in CIA rats
In the development and progression of various autoimmune diseases including RA, Th17 cells play a vital inductive role, whereas Treg cells are functionally defective. To recognize whether berberine could alter the populations and cell responses of Th17 and Treg cells in CIA rats, flow cytometric analysis and ELISA were performed, respectively. As shown in Fig. 2A ,B, CIA rats exhibited a markedly increased Th17 cell response and slightly increased Treg cell response. Berberine treatment markedly down-regulated the frequency of Th17 cells in blood and the IL-17 level in serum. Quantitative PCR analysis confirmed the down-regulatory effect of berberine on the expressions of Th17 transcription factor retinoic acid receptor-related orphan receptor gamma t (RORct) in the spleen (Fig. 2C ) and IL-17 in synovium (Fig. 2E ). Western blotting assay showed that berberine could attenuate the phosphorylation of signal transducer and activator of transcription 3 (STAT3), a transcription factor critical for Th17 differentiation (Fig. 2D ). In contrast, berberine treatment did not significantly influence the frequency of Treg cells, the serum level of IL-10 and the expression of forkhead box P3 (Foxp3) ( Fig. 2A-C) .
Absorbed berberine was insufficient to exhibit an anti-arthritic effect
It is well known that orally administered berberine is hardly absorbed by the gastrointestinal tract, and the plasma and tissue concentrations of berberine itself and its metabolites are extremely low. To exclude the potential possibility that little absorbed berberine exerts direct immunosuppressive and/or anti-inflammatory action and therefore attenuates arthritis, an intravenous administration experiment was performed.
The results showed that an intravenous injection of berberine at a dose of 2 mgÁkg À1 (1% of the oral dose based on the fact that the bioavailability of berberine is less than 1%) failed to affect the expression of Th17/Treg transcription factors and arthritis symptoms in CIA rats (Fig. 3) . It was, therefore, postulated that absorbed berberine after oral administration was not enough to directly attenuate arthritis, and the action mode of berberine might be intestine dependent.
Berberine selectively induced the generation of CST in the small intestines of CIA rats Multiple gastrointestinal neuropeptides can regulate systemic T-cell responses in autoimmune diseases. To clarify how unabsorbed berberine that accumulated in gastrointestinal tract attenuated systemic symptom of CIA rats, we analyzed the contribution of the intestinal endocrine system by detecting the mRNA expressions of five immunoregulatory neuropeptides in small intestines of CIA rats, including VIP, somatostatin (SST), ghrelin, CST, and substance P (SP). As shown in Fig. 4A ,B, although synovial mRNA levels of the five neuropeptides were not markedly affected by berberine treatment, intestinal mRNA and protein levels of CST dramatically increased in berberine-treated rats, which was followed by the increase of the plasma protein level of CST. Berberine also moderately promoted the expression of SST mRNA in intestines, but showed no significant effect on the protein level of SST in both intestine and serum of CIA rats. To further address the origin of CST in the circulation of berberine-treated rats, we detected the mRNA expression of CST in both cerebral cortex and spleen, the other two main generation sites of CST in addition to gut, and found that the CST mRNA levels in the two sites were not markedly affected by berberine (Fig. 4C ). The findings revealed that oral berberine selectively induced the generation of CST from the intestines of CIA rats, and CST then entered into the circulation.
Serum CST level negatively correlated with the pathological changes of joints in berberinetreated CIA rats Based on the findings mentioned above, we wondered whether the elevated serum level of CST by berberine was related to the anti-arthritic effect. To verify this issue, a Spearman bivariate correlation analysis was conducted. The results showed that the serum CST levels were highly negatively correlated with arthritis index, paw swelling, histological scores, and Th17 (G) The serum levels of TNF-a, IL-6, and IL-1b were measured by ELISA. Data were expressed as means AE SEM, n = 6. ## P < 0.01 vs normal; *P < 0.05 and **P < 0.01 vs model.
frequency of blood in berberine-treated CIA rats (Fig. 5) , implying that CST might be an important mediator for the anti-arthritic efficacy of oral berberine.
CST receptor antagonists reversed the inhibition of Th17 response and anti-arthritic efficacy of berberine in CIA rats
To confirm the contribution of CST in berberinemediated suppression of Th17 cell response and arthritis, CST receptor antagonists were coadministered with berberine in CIA rats. The antagonists of somatostatin receptors (SSTRs) and ghrelin/growth hormone secretagogue receptor 1 (GHSR1) were used to verify the involvement of CST in the anti-arthritic effect of berberine and to clarify the receptor subtype by which CST acts in inhibiting the Th17 cell response. The results showed that coadministration with [D-Lys3]-growth hormone-releasing peptide 6 (D-Lys3; an antagonist of GHSR1), but not cyclo-somatostatin (C-SST; an antagonist of SSTR1-5) strikingly abated the suppression of the Th17 cell response and arthritis by berberine (Figs 6A-D and 7A,C,E). To further verify the contributions of CST and GHSR1, YIL-781, another antagonist of GHSR1 with a quinazolinone structure (distinct from D-Lys3), was coadministered with berberine. As shown in Figs 6E-H and 7B,D,F, YIL-781 also abolished berberine-mediated inhibition of the Th17 cell response and arthritis in CIA rats. These findings revealed that gut-derived CST mediated the attenuation of berberine on the Th17 cell response and consequent arthritis in CIA rats via GHSR1.
Berberine promoted CST generation from neurons via phosphoinositide 3-kinase-related pathways CST is originally described to express in cortex and hippocampus. More recently, peripheral neurons and gastrointestinal tract, in particular d cells, are also recognized to express CST [13] . Here, we evaluated the effect of berberine on the generation of CST in nerve growth factor-induced PC12 cells (neural cell line) and STC-1 cells (gastrointestinal endocrine cell line) ). [22, 23] . As shown in Fig. 8A, 3 -60 lM of berberine exhibited little cytotoxicity on the two cells, and the concentrations were used in the following in vitro studies. Fig. 8B ,C showed that berberine concentration dependently induced the expression of CST at mRNA and protein levels in PC12 cells. In contrast, up to 60 lM, berberine failed to induce CST expression in STC-1 cells. Next, we added several specific inhibitors of the signal pathways into PC12 cells together with berberine to identify the key signaling pathway. The results showed that LY-294002 (an inhibitor of phosphoinositide 3-kinase; PI3K) nearly completely reversed berberine-induced expression of CST in PC12 cells, but KN62, PD098059 and H-89 (inhibitors of Ca 2+ / calmodulin-dependent protein kinases, extracellular signal-regulated kinase, and protein kinase A, respectively) did not affect the action of berberine (Fig. 8D) , implying that berberine might induce the expression of CST through a PI3K-related pathway.
Berberine induced the expression of CST through an autocrine/paracrine action To simulate an in vivo environment, PC12 cells were cocultured with endocrine cells (STC-1 cells) , in which berberine up to 60 lM showed a lack of marked effect on CST expression (Fig. 8B,C) . Interestingly, we found that berberine (30 and 60 lM) upregulated the expression of CST in the coculture system more potently than it did in PC12 cells only (Fig. 9A,B) . To recognize why berberine-induced CST expression was increased in the coculture system, we examined the mRNA expression of CST in both PC12 and STC-1 cells. Different from the results obtained from separate culture, STC-1 cells under coculture condition expressed a relatively high level of CST mRNA in the presence of berberine (Fig. 9C) . When STC-1 cells were cultured with the supernatants of PC12 cells acquired 2 h after the treatment of berberine (60 lM), the expression of CST was also markedly elevated (Fig. 9D) . The antagonists of CST receptors could abolish the promotion effect of the supernatants of PC12 cells. Moreover, the mRNA expression of CST in STC-1 cells could be markedly promoted by a recombinant protein of CST (Fig. 9E) . Taken together, the results led us to conclude that berberine might exert a more 
Discussion
Besides the traditional usage as a medicine to ameliorate gastroenteritis and diarrhea, berberine shows potential for treating diabetes, hyperlipidemia, and several autoimmune diseases [24] . However, after intragastric dosing, most of berberine prototype and its metabolites were eliminated in feces, resulting in an extremely low oral bioavailability of 0.36% [10] . Similarly, a number of natural compounds isolated from the herbal medicines also exhibit excellent pharmacological effects despite poor pharmacokinetic behaviors, but unfortunately, there is no widely accepted explanation for this pharmacokinetic-pharmacodynamic disconnection so far. In this study, gut-sourced neuropeptide CST was identified as a key mediator of berberine for the attenuation of systemic Th17 cell response and consequent arthritis.
It has been well documented that the imbalance between Th17 cells and Treg cells contributes to the development and progression of RA and CIA. Th17 cells promote the development of RA and CIA: increased frequencies of Th17 cells were observed in both synovial fluid and peripheral blood of RA patients; mice deficient in IL-17 are protected from the development of arthritis; treatment with IL-17R antagonist or IL-17 neutralizing antibody can attenuate arthritis in mice accompanied by decreased joint damage and a reduced serum IL-6 level [25, 26] . In contrast to Th17 cells, Treg cells are generally functionally defective in patients with RA: Treg cells are enriched in joint synovial fluid of RA patients, working to suppress aberrant inflammatory responses and limit the effects of Th17 cells by reducing its accumulation at the site of inflammation [27, 28] . Our findings that berberine could attenuate the Th17 cell response were consistent with the recent reports that berberine treatment could suppress the Th17 response in dextran sodium sulfate-and TNBS-induced colitis, type 1 diabetes, EAE, and experimental autoimmune myocarditis [29] [30] [31] [32] [33] . Therefore, we came to the first conclusion that berberine was effective in alleviating ongoing severity of rat CIA, and that the underlying mechanisms involved the inhibition of the systemic Th17 cell response. Considering the extremely low oral bioavailability of berberine, we wondered whether the absorbed berberine was sufficient to attenuate the systemic Th17 cell response and consequent arthritis in rat. An intravenous injection of berberine failed to ameliorate the arthritis in rats, indicating that the systemic effect of oral berberine did not result from its absorbed part. As oral berberine is preferentially effective in the treatments of gastrointestinal disorders and most of its prototype and metabolites are excreted in feces, the gut can be considered as the main target organ of berberine for anti-arthritic effect. The following question then arises: What is the connection between berberine in the gut and symptom alleviation in joints of rats?
The intestinal tract is known to be the largest endocrine organ and responsible for the secretion of multiple neuropeptides, hormones, and cytokines. As reported previously [5] , a number of neuropeptides function as anti-inflammatory and immune-modulation agents. Recent findings also indicated that several herbal medicines including berberine may regulate the secretion of neuropeptides [34, 35] . Therefore, increasingly generated CST may be the connection because the CST level theoretically correlated with the antiarthritic efficacy of berberine. CST has been recognized as an important endogenous regulator in the immune system that can inhibit the activation and differentiation of T lymphocytes. During the last decade, CST was found to have therapeutic potential in disorders such as inflammatory bowel disease, RA, and multiple sclerosis. Intraperitoneal injection of CST was shown to reduce the severity of disease symptoms and the presence/activation of pathological Th1 and Th17 cells in mice with TNBS-induced colitis, CIA, or EAE [19, 20, 36] . As a member of the SST neuropeptide family, CST can bind to three G protein-coupled receptors, namely SSTRs GHSR1 and Mas-related gene X2 (MrgX2). SSTRs and GHSR1 are mainly involved in the antiinflammatory, immune modulatory, and analgesic effects of CST. Herein, two GHSR1 antagonists with different structure types almost completely abolished the anti-arthritic and Th17 suppressive effects of berberine, indicating that berberine exerted inhibitory effects on the Th17 response and arthritis through gut-derived CST, and the latter functioned through GHSR1.
The generation of CST was initially identified in scattered gamma-aminobutyric acid-ergic interneurons of the cerebral cortex and hippocampus. Further studies demonstrated the expression of CST in various peripheral tissues and cells, including peripheral neurons and gastrointestinal track, especially scattered enteroendocrine d cells [36] . The detailed mechanism of CST expression is still far from fully understood. In this study, we found that berberine could directly induce CST expression in nerve cells (differentiated PC12 cells) but not endocrine cells (STC-1 cells), and this induction effect was PI3K-related. Further studies on the regulatory mechanism of CST expression would enable us to recognize the reason why berberine selectively induced CST rather than other neuropeptides in gastrointestinal tract of CIA rats.
According to our data, berberine could induce the expression of CST in either gut or nerve cells of CIA rats. However, the in vitro potency of berberine seemed far lower than that in vivo. These findings implied that berberine might induce CST expression by not or just partially directly affecting nerve cells. The intestinal tract is a highly complex organ that consists of many cell types of different embryonic origins, mainly including epithelial cells, nerve cells, endocrine cells, and immune cells. The interaction between these cells possibly contributes to the promotion of CST expression. In fact, our data demonstrated that CST originating from the enteric nerve cells induced by oral berberine may promote the generation of CST in enteric endocrine cells. In accordance with this, there were reports indicating that the generation of CST, similar to SST, could be regulated by an autocrine/paracrine action. A small amount of CST produced by nerve cells might trigger the expression of CST in other cell types [37] [38] [39] . Thus, we postulated that oral administration of berberine in CIA rats might moderately trigger the generation of CST in enteric neurons, and the CST induce a marked expression of CST in enteric neurons and endocrine cells through an autocrine/paracrine action, and finally result in a marked elevation of CST level in intestines and the circulation. In summary, we described that berberine ameliorated rat CIA by promoting CST generation in the gut. The up-regulated CST entered the circulation, suppressed the systemic Th17 cell response, and alleviated arthritis. The findings provide a novel explanation for the anti-arthritic effects of berberine and other compounds with similar pharmacokinetic characteristics. Gut-sourced neuropeptides and relevant receptors might be potential drug targets for the treatment of systemic autoimmune diseases.
Materials and methods
Reagents
Berberine (purity ≥ 98%) was purchased from Zelang Pharmaceutical Technology Co., Ltd (Nanjing, China). Leflunomide was purchased from Cinkate Pharmaceutical Corp. (Suzhou, China). Chicken CII and YIL-781 (a specific antagonist of GHSR1) were purchased from Sigma-Aldrich (St Louis, MO, USA). Mycobacterium butyricum was purchased from Becton Dickinson (Franklin Lakes, NJ, USA). C-SST, a nonselective antagonist of SST receptor, was purchased from APExBIO Co., Ltd (Shanghai, China). DLys3, a specific antagonist of GHSR1, was purchased from GL Biochem Co., Ltd (Shanghai, China). LY294002 (a specific inhibitor of PI3K) and NP 40 buffer were purchased from Beyotime Co. (Jiangsu, China 
Collagen-induced arthritis and treatment
CIA was established in rats with reference to the method described previously [40] . Briefly, CII was emulsified in complete Freund's adjuvant (1 mgÁmL À1 ). On day 0, CII emulsion was intradermally injected at the base of the rat tail with a volume of 0.2 mL. On day 7, a booster immunization was conducted with a volume of 0.1 mL at the base of the rat tail, avoiding the primary injection sites. Rats were observed daily for clinical signs of arthritis, and each paw was scored on a scale of 0-4 as follows: 0 = no swelling or erythema, 1 = slight swelling and or erythema, 2 = low to moderate edema, 3 = pronounced edema with limited joint usage, and 4 = excess edema with joint rigidity. The total score for each rat was calculated as an arthritis index with a maximum value of 16. The volumes of hind paws were determined by a paw volume plethysmometer. For the oral administration study, rats were intragastrically administered with berberine (100, 200 mgÁkg À1 ) or leflunomide (2 mgÁkg À1 ) from day 14 to day 28. For the alternative intravenous administration study, berberine (2 mgÁkg À1 ) was intravenously injected through the tail vein. C-SST, D-Lys3, and YIL-781 were dissolved in saline and injected intraperitoneally.
Cell preparation and culture
PBMCs and splenocytes of arthritic rats were freshly isolated and resuspended in RPMI-1640 supplemented with 10% fetal bovine serum. STC-1 and PC12 cell lines (ATCC, Manassas, VA, USA) were maintained in RPMI-1640 and DMEM/F12 medium, respectively. Both of them were supplemented with 10% fetal bovine serum, 100 UÁmL À1 of penicillin, and 100 UÁmL À1 of streptomycin. All these cells were maintained at 37°C under a humidified 5% CO 2 atmosphere. STC-1 and PC12 cells were seeded on 96-well or 48-well plates, pretreated with or without LY294002, KN62, PD098059, H-89, C-SST, DLys3, and YIL-781, and then treated with berberine (5, 10, 30, 60 lM) for 2 h. The supernatants were collected for cytokine assay using ELISA kits.
For coculture experiments, PC12 cells were seeded on one side of a collagen vitrigel membrane (diameter of 30 mm) and exposed to recombinant mouse nerve growth factor (10 ngÁmL À1 ). The membrane was then inverted in another dish, and STC-1 cells were seeded on the empty side. The supernatant was collected for cytokine assay using ELISA kits.
Flow cytometry
With reference to the method described previously [41] , PBMCs and splenocytes resuspended in RPMI-1640 supplemented with 10% fetal bovine serum were labeled with FITC-anti-CD4 and APC-anti-CD25 at 4°C for 30 min. After fixation and permeabilization, the cells were labeled with APC-anti-IL-17 or phycoerythrin-anti-Foxp3 at 4°C for 30 min. All flow cytometric measurements were conducted on FACSCalibur (BD Biosciences, San Jose, CA, USA). Results were analyzed using Flowjo 10.0.1 (Flowjo LLC, Ashland, OR, USA).
Histopathological examination
Rats were euthanized with an excess dose of chloral hydrate hydrochloride at the termination of the experiment on day 28. The ankle joints were taken and fixed in 10% neutral buffered formalin for 48 h, decalcified in EDTA, embedded in paraffin, and sliced into 5 mm-thick sections. HE staining was performed, and histological changes in joints were determined by a pathologist blinded to the experimental group, and scored according to the degree of hyperplasia inflammatory cell infiltration, synovial hyperplasia and congestion, fibrous tissue hyperplasia, and bone erosion and regeneration.
Radiological scanning
Rats were euthanized with chloral hydrate hydrochloride and X-rayed on day 28. Joint destruction was determined by a pathologist blinded to the experimental group and scored on a scale of 0-3, where 0 = no joint erosion, 1 = mild joint erosion, 2 = moderate joint erosion, and 3 = severe joint erosion.
Quantitative PCR assay
Total RNA from synovial and small intestine tissues of rats, STC-1 cells ,or PC12 cells was extracted with TRIzol reagent and reverse transcribed to cDNA. The expressions of SST, VIP, ghrelin, SP, CST, retinoic acid receptor-related orphan receptor C (RORC), and Foxp3 were analyzed by Ace qPCR SYBR Green Master Mix (Richmond, Canada) and normalized to GAPDH. The primer sequences were as follows: RORC: forward 5 0 -GAA GGC AAA TAC GGT GGT GT- 
ELISA assay
Cytokine and neuropeptide levels in serum, tissue, and cell supernatant were measured using ELISA kits according to the manufacturers's instructions. Briefly, (a) 100 lL sample and 50 lL biotinylated antibodies were added per well, and plates were closed with plate closure membranes and incubated at 37°C for 60 min; (b) plate closure membrane was removed, liquid was discarded, it was dried by swinging, washing buffer was added to every well, it was kept still for 30 s and then drained, this was repeated three times, and it was dried by patting; (c) 100 lL streptavidin-horseradish peroxidase was added per well, plates were closed with plate closure membranes and incubated at 37°C for 30 min; (d) step (b) was repeated; (e) 100 lL 3, 3', 5, 5'-tetramethylbenzidine was added per well, it was preserved in the absence of light for 15 min at 37°C, and the reaction was stopped with stop solution.
Western blotting assay
Proteins from spleen tissues were extracted with NP40 buffer. Samples were separated on 10% SDS/PAGE gel and transferred to PVDF membranes. The membranes were blocked with 5% nonfat milk for 2 h and incubated with specific primary antibodies at 4°C overnight. After being rinsed, membranes were further incubated with IRDye-conjugated secondary antibody for 2 h at room temperature. Detection was performed by the Odyssey Infrared Imaging System.
Cell viability assay
The viability of STC-1 and PC12 cells were determined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates, treated with berberine for 24 h, and 20 lL of MTT solution (5 mgÁmL À1 ) added 4 h before the end of incubation. Then, the supernatant was removed, and the formazan crystal was dissolved with 150 lL of DMSO. After 10 min, the optical absorbance at 570 nm was read with a Model 1500 Multiskan spectrum microplate Reader (Thermo Fisher Scientific, Waltham, MA, USA).
Statistical analysis
Data of in vivo and in vitro experiments were presented as the mean AE standard error of mean (SEM). Comparisons between multiple groups were performed using one-way ANOVA and Tukey's post hoc test. P values less than 0.05 were considered to be statistically significant.
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